S-1: Biofrontera Inc. Eyes Public Offering to Bolster Growth Strategies

Biofrontera Inc. announces a proposed public offering of common stock and warrants to fuel working capital and growth initiatives.

Summary

• Biofrontera Inc., a biopharmaceutical company specializing in dermatological treatments, is planning a public offering.
• The offering includes shares of common stock and warrants to purchase additional shares.
• Pre-funded warrants may also be offered to investors whose ownership would exceed certain thresholds.
• Roth Capital Partners, LLC is acting as the sole placement agent for the offering.
• The company intends to use the net proceeds for general corporate purposes, including working capital and investments in growth strategies.
• The offering is being conducted on a best efforts basis, and the company may sell fewer than all of the securities offered.
• The company believes that the net proceeds from this offering, together with cash on hand and other strategic initiatives, will satisfy its capital needs until break even in mid-2025.
• If the company does not receive a minimum of $ million in net proceeds from this offering or from other sources of financing by the end of 2024, it will need to seek additional alternatives to raise additional capital to fund its operations, continue to support its planned development and commercialization activities, and pay certain obligations that are coming due in 2024, or it will need to reduce its expenditures and renegotiate such obligations.

Sentiment

Score: 5

Explanation: The announcement is neutral. While it outlines a plan for raising capital, it also acknowledges existing financial challenges and potential risks.

Positives

• The company intends to use the net proceeds from this offering for general corporate purposes, including working capital and continued investments in our growth strategies.
• The company believes that the net proceeds from this offering, together with cash on hand and other strategic initiatives, will satisfy its capital needs until break even in mid-2025.

Negatives

• The offering is being conducted on a best efforts basis, and the company may sell fewer than all of the securities offered.
• There is no established public trading market for the warrants to be issued in this offering or the pre-funded warrants, and we do not expect such a market to develop.
• If the company does not receive a minimum of $ million in net proceeds from this offering or from other sources of financing by the end of 2024, it will need to seek additional alternatives to raise additional capital to fund its operations, continue to support its planned development and commercialization activities, and pay certain obligations that are coming due in 2024, or it will need to reduce its expenditures and renegotiate such obligations.

Risks

• The actual combined public offering price per share or pre-funded warrant, as the case may be, and accompanying warrant to purchase shares of common stock in this offering will be determined between us, the Placement Agent and the investors in this offering at the time of pricing, and may be at a discount to the current market price for our Common Stock.
• Investing in our securities involves a high degree of risk.
• If we are not able to successfully renegotiate such obligations, such non-payment would have a material adverse effect on our financial condition.

Future Outlook

Assuming that we receive a minimum of $ million of net proceeds from this offering, we believe that the net proceeds from this offering, together with our cash on hand and other strategic initiatives, will satisfy our capital needs until break even in mid-2025.

Industry Context

The pharmaceutical and medical device industry is characterized by intense competition and rapid innovation.

Comparison to Industry Standards

• Our primary competitor in the PDT space is Levulan and the associated light, Blu-U.
• Levulan is approved for spot-therapy of mild to moderate AK on the face and scalp and AK on the upper extremities

Stakeholder Impact

• The offering could dilute the ownership of existing stockholders.
• The company's ability to execute its growth plan and raise additional capital will impact its ability to meet its obligations and sustain its operations.

Next Steps

• The offer will terminate on , 2024, unless completed sooner or unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date.
• We expect this offering to be completed not later than two business days following the commencement of sales in this offering (after the effective date of the registration statement of which this prospectus forms a part), and we will deliver all securities to be issued in connection with this offering delivery versus payment/ receipt versus payment upon receipt by us of investor funds.

Key Dates

Keywords

public offering, common stock, warrants, Biofrontera, placement agent, securities, pre-funded warrants, BFRI, capital raise